IXICO Plc
http://ixico.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From IXICO Plc
CEO Kevin Ali Marks Organon’s Progress In First Post-Spin Year
A year after Organon spun out of Merck, the company has delivered on its financial guidance, generated double-digit biosimilars sales growth and executed six deals to grow in women’s health.
Hereditary Angioedema Market Snapshot: Room For Pills And Injections As Prophylaxis Makes Gains
While many HAE patients converted from injectable prophylaxis to BioCryst’s oral Orladeyo last year, physicians said a promising injectable candidate from Ionis could benefit from varied patient preference.
Finance Watch: Q1 Biopharma IPOs Shrink To A Fraction Of 2021 Total
Public Company Edition: Only nine drug developers went public in the US, raising $807m in the first quarter, versus 32 IPOs raising $5.2bn in Q1 of last year. Also, MoonLake closed its SPAC merger, Sanofi priced €650m in sustainability-linked bonds in €1.5bn note sale, and Kaleido will cease operations.
How Organon Expects To Steer Its Women’s Health Engine In India
Organon commercial director and lead for the South Asia Region, Anjan Sen, lays out how the Merck spin-out expects to scale up activities in markets like India. A mix of new products, targeted repurposing efforts and access-driven pricing are part of the strategy that could potentially see the company double its presence in the region.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- MRI, NMR
- Ultrasound
- X-ray
-
Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
-
- IXICO Technologies Inc.
- Optimal Medicine Inc.
- Phytopharm plc